TY - JOUR
T1 - β-D-glucan as a diagnostic adjunct for invasive fungal infections
T2 - Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome
AU - Odabasi, Zekaver
AU - Mattiuzzi, Gloria
AU - Estey, Elihu
AU - Kantarjian, Hagop
AU - Saeki, Fumihiro
AU - Ridge, Richard J.
AU - Ketchum, Paul A.
AU - Finkelman, Malcolm A.
AU - Rex, John H.
AU - Ostrosky-Zeichner, Luis
N1 - Funding Information:
Financial support. Grant from Associates of Cape Cod. Conflict of interest. F.S., R.J.R., P.A.K., and M.A.F. are employed by Associates of Cape Cod. L.O.-Z. and J.H.R. have received research grants from Associates of Cape Cod. All other authors: No conflict.
PY - 2004/7/15
Y1 - 2004/7/15
N2 - The Glucatell (1→3)-β-D-glucan (BG) detection assay (Associates of Cape Cod) was studied as a diagnostic adjunct for invasive fungal infections (IFIs). On the basis of findings from a preliminary study of 30 candidemic subjects and 30 healthy adults, a serum BG level of ≥60 pg/mL was chosen as the cutoff. Testing was performed with serial serum samples obtained from 283 subjects with acute myeloid leukemia or myelodysplastic syndrome who were receiving antifungal prophylaxis. At least 1 serum sample was positive for BG at a median of 10 days before the clinical diagnosis in 100% of subjects with a proven or probable IFI. IFIs included candidiasis, fusariosis, trichosporonosis, and aspergillosis. Absence of a positive BG finding had a 100% negative predictive value, and the specificity of the test was 90% for a single positive test result and ≥96% for ≥2 sequential positive results. The Glucatell serum BG detection assay is highly sensitive and specific as a diagnostic adjunct for IFI.
AB - The Glucatell (1→3)-β-D-glucan (BG) detection assay (Associates of Cape Cod) was studied as a diagnostic adjunct for invasive fungal infections (IFIs). On the basis of findings from a preliminary study of 30 candidemic subjects and 30 healthy adults, a serum BG level of ≥60 pg/mL was chosen as the cutoff. Testing was performed with serial serum samples obtained from 283 subjects with acute myeloid leukemia or myelodysplastic syndrome who were receiving antifungal prophylaxis. At least 1 serum sample was positive for BG at a median of 10 days before the clinical diagnosis in 100% of subjects with a proven or probable IFI. IFIs included candidiasis, fusariosis, trichosporonosis, and aspergillosis. Absence of a positive BG finding had a 100% negative predictive value, and the specificity of the test was 90% for a single positive test result and ≥96% for ≥2 sequential positive results. The Glucatell serum BG detection assay is highly sensitive and specific as a diagnostic adjunct for IFI.
UR - http://www.scopus.com/inward/record.url?scp=3242771193&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242771193&partnerID=8YFLogxK
U2 - 10.1086/421944
DO - 10.1086/421944
M3 - Article
C2 - 15307029
AN - SCOPUS:3242771193
SN - 1058-4838
VL - 39
SP - 199
EP - 205
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 2
ER -